|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||83.75 - 83.75|
|52 Week Range||49.00 - 84.50|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||40.25|
|Forward Dividend & Yield||1.47 (1.75%)|
|Ex-Dividend Date||Mar 29, 2020|
|1y Target Est||N/A|
Eisai Co. Ltd. said Thursday that it would pull its weight-loss drug Belviq off the market in the U.S. A long-term trial, which studied the drug's cardiovascular impact, was required as part of the Food and Drug Administration approval in 2012. This study found that people taking the drug reported higher rates of cancer than those taking the placebo. Eisai said it still believes Belviq has a positive benefit-risk profile for the patients for which it is indicated but would still pull the drug from the market. "Eisai's interpretation of the data from the Camellia-Timi 61 trial differs from that of the FDA," the company said in a news release. Eisai's stock is up 4% over the past year, compared to the S&P 500 , which has gained 22%.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
Shares in Eisai Co , Biogen's Japanese partner in the drug, were quoted up 18% to the daily limit high of 6,534 yen in Tokyo trading. The field of experimental Alzheimer's treatments is littered with high-profile failures, with many major drugmakers abandoning the race to develop a medicine for a disease that makes up 60%-70% of an estimated 50 million dementia cases globally. Any medicine that effectively treats the disease is likely to become one of the world's top-selling drugs and could be transformative for Biogen, which is facing multiple challenges over its product pipeline.
Biogen stock popped in relief Friday after the biotech company scrapped several tests in Alzheimer's treatment for a drug known as elenbecestat. It was being developed with Japan's Eisai.
Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease. The companies said on Friday the decision was based on the results of a review conducted by a data safety monitoring board, which recommended discontinuing the trials as benefits from the treatment, elenbecestat, did not outweigh its risks. Shares of Biogen were up 2.3% at $237.60 as some analysts said ending the trial would save the company costs associated with running it through its completion.
Japanese drug maker Eisai Co., Ltd (OTC: ESALY ) has some positive news concerning one of its pipeline candidates. What Happened Eisai said the FDA has granted Breakthrough Therapy Designation for Lenvima, ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Lenvima growth trendsIn the first quarter, Merck’s (MRK) and Eisai’s Lenvima reported solid uptake across multiple markets, driven mainly by demand in
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 28) Baxter International Inc (NYSE: BAX ) Constellation ...
On Friday, the spread between yields of U.S. three-month Treasury bills exceeded those of 10-year notes for the first time since 2007. The inversion of the Treasury yield curve suggested the world's largest economy could slide into recession and reignited fears of a deepening slowdown in the global economy. "Insurers react negatively as it becomes harder for them to manage assets," said Eiji Kinouchi, chief technical analyst at Daiwa Securities.
Japan's Nikkei sold off sharply on Monday as investors moved into bonds and other assets perceived as safe amid renewed fears of a global economic slowdown. The benchmark index was on track for its steepest daily fall in percentage terms since losing 5 percent in late December. On Friday, the spread between yields of U.S. three-month Treasury bills exceeded those of 10-year notes for the first time since 2007.
Biogen and Japanese pharma Eisai announced a new study in Alzheimer's disease treatment Friday following a high-profile failure on Thursday that sent Biogen stock into a tailspin.
Mizuho Securities analyst Salim Syed downgraded Biogen from Buy to Neutral and slashed the price target from $416 to $235. UBS analyst Carter Gould downgraded Biogen from Buy to Neutral and reduced the price target from $395 to $242. Morgan Stanley analyst Matthew Harrison downgraded shares from Overweight to Underweight and slashed the price target from $401 to $210.
Eisai, which is partnering with Biogen Inc (NASDAQ: BIIB) on Alzheimer's research, announced the initiation of a global Phase 3 clinical study Thursday, dubbed Clarity AD/Study 301, of BAN2401, which is being evaluated in patients with early Alzheimer's disease. BAN2401 is a monoclonal antibody that acts against beta-amyloid protein that forms clumps called plaques in the brain, impairing connections between brain cells and triggering inflammation, leading to cell death, both of which are responsible for the onset of Alzheimer's.
Japan's Nikkei ended little changed on Friday as chip-related stocks offset weakness in financial stocks and drugmakers, which tumbled after Eisai said it will end its Alzheimer drug trials. Advantest Corp soared 6.2 percent and Tokyo Electron surged 5.2 percent. "The U.S. tech sector's recovery is indicating that growth stocks are making a come back," said Norihiro Fujito, a chief investment strategist at Mitsubishi UFJ Morgan Stanley Securities.
Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab. On Friday, Eisai was untraded, flooded with sell orders at 7,565 yen, almost 17 percent lower than its previous close. The demise of aducanumab came after independent experts determined the trials had little hope of succeeding, marking the latest setback in the quest to treat a mind-wasting disease that affects 5.7 million people in the United States alone.